Litchfield Hills analyst Theodore O’Neill initiated coverage of Inspira Technologies (IINN) with a Buy rating and $2 price target Inspira is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, the analyst tells investors in a research note. The firm says the company has a “well-protected technology moat” that includes both patented technology and technical trade secrets.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance
- Inspira Technologies Launches Global Rollout of ART100 System
- Inspira initiates global commercial rollout of ART100 system
- Inspira Technologies Restructures Executive Team for Strategic Alignment
- Inspira Technologies president Joe Hayon steps down
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue